US 11,684,591 B2
Use of a GABAA receptor allosteric enhancer in medicine
Rutao Wang, Xi'an (CN); Long An, Xi'an (CN); Yi Zhao, Xi'an (CN); Jinghua Pang, Xi'an (CN); Tao Chen, Xi'an (CN); and Weijiao Wang, Xi'an (CN)
Assigned to XI'AN LIBANG ZHAOXIN BIOTECHNOLOGY CO., LTD, Xi'an (CN)
Appl. No. 17/271,828
Filed by XI'AN LIBANG ZHAOXIN BIOTECHNOLOGY CO., LTD., Xi'an (CN)
PCT Filed Jul. 10, 2019, PCT No. PCT/CN2019/095395
§ 371(c)(1), (2) Date Feb. 26, 2021,
PCT Pub. No. WO2020/042767, PCT Pub. Date Mar. 5, 2020.
Claims priority of application No. 201811011320.1 (CN), filed on Aug. 31, 2018.
Prior Publication US 2021/0315835 A1, Oct. 14, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/05 (2006.01); A61P 25/08 (2006.01)
CPC A61K 31/05 (2013.01) [A61P 25/08 (2018.01)] 3 Claims
 
1. A method of treating epilepsy, comprising administering a GABAA receptor allosteric enhancer represented by formula (I):

OG Complex Work Unit Chemistry